June 12, Hybio Pharmaceutical released the record of investor relations activities. HY3003 is a GLP-1R/GIPR/GCGR triple-target receptor agonist screened by Hanyu Pharmaceuticals and its partners using AI peptide chip technology for weight loss indications. As of this week, the preclinical optimal candidate compound screening and API process development have been completed, and the API pilot scale-up stage has officially begun. In addition to triple-target weight loss drugs, the company also has 1.1-class innovative drugs. HY3000 nasal spray, which is indicated for the prevention of coronavirus infection, is currently in the phase III clinical trial stage. In terms of the exploration of innovative cannabidiol (CBD) drugs , the company has established a partnership with Sinopharm In-depth cooperation is carried out in the fields of research and development of innovative cannabidiol (CBD) drugs , integration of peptide and small nucleic acid drug technologies, and commercial promotion. In terms of clinical progress, the Phase III clinical trial of semaglutide injection has completed the enrollment of all subjects in January this year. It is currently in the follow-up stage, and the project has entered the dose maintenance period. It is expected to be listed in China in 2026, followed by the United States and many countries around the world.

https://finance.eastmoney.com/a/202506123429068762.html